Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05212597
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05212597
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05212597. Randomized; no masking; primary purpose treatment. Start 2022-01-12 (actual); primary completion 2023-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
- Acronym
- REVERSE-AR
- Condition
- Aortic Valve Insufficiency
- Intervention (Drug)
- Sacubitril-valsartan
- Intervention (Drug)
- Amlodipine-losartan
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct05212597- Content hash
569099b818ead6cbaf51218194d1b41736310a7a9e752ff670cca9e81f713f78